|
Cem Akin, M.D., Ph.D.
National Institute of Allergy and
Infectious Diseases
Joseph Antin, M.D.
Dana-Farber Cancer Institute
Harvard Medical School
Giovanni Barosi, M.D.
Laboratory of Medical Informatics
IRCCS Policlinico S. Matteo
A. John Barrett, M.D.
Hematology Branch
National Heart, Lung, and Blood Institute
Henry Chang, M.D.
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Helen Chen, M.D.
Cancer Therapy Evaluation Program, DCTD
National Cancer Institute
Bruce D. Cheson, M.D.
Cancer Therapy Evaluation Program, DCTD
National Cancer Institute
Michaele C. Christian,
M.D.
Cancer Therapy Evaluation Program, DCTD
National Cancer Institute
A. Dimitrios Colevas,
M.D.
Cancer Therapy Evaluation Program, DCTD
National Cancer Institute
Janet Dancey, M.D.
Cancer Therapy Evaluation Program, DCTD
National Cancer Institute
Gordon Dewald, Ph.D.
Division of Laboratory Genetics
Mayo Clinic
Cynthia E. Dunbar,
M.D.
Hematology Branch
National Heart, Lung, and Blood Institute
Bonni S. Dutcher,
Ph.D.
Senior Medical Therapeutic Liaison
Sanofi~Synthelabo
Peter D. Emanuel,
M.D.
Division of Hematology/Oncology
University of Alabama at Birmingham
Ann T. Farrell, M.D.
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Steven Fruchtman,
M.D.
Associate Professor of Medicine
Mount Sinai Hospital
Gregory K. Frykman,
M.D.
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Francis J. Giles,
M.D.
University of Texas M.D. Anderson
Cancer Center
Jay Greenblatt, Ph.D.
Cancer Therapy Evaluation Program, DCTD
National Cancer Institute
Mala Hermon
Patient Advocate
Amna Ibrahim, M.D.
Division of Oncologic Drug Products
U.S. Food and Drug Administration
LeeAnn Jensen, Ph.D.
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Richard S. Kaplan,
M.D.
Cancer Therapy Evalutaion Program, DCTD
National Cancer Institute
Scott E. Kaufmann,
M.D., Ph.D.
Pharmacology and Medicine
Mayo Clinic
H. Phillip Koeffler,
M.D.
Cedars-Sinai Medical Center
University of California Los Angeles
Sanford Krantz, M.D.
Nashville VA Medical Center
Vanderbilt University
Richard A. Larson,
M.D.
Department of Hematology/Oncology
University of Chicago
Magnus K. Magnusson,
M.D.
National Heart, Lung, and Blood Institute
Linda McClure, R.N.,
M.S.
Cancer Therapy Evaluation Program, DCTD
National Cancer Institute
Beverly Meadows, R.N.,
M.S., O.C.N.
Clinical Trials Development and Informatics
Cancer Therapy Evaluation Program, DCTD
National Cancer Institute
Junia V. Melo, M.D.,
Ph.D.
Department of Haemabology - ICSTM
Imperial College/Hammersmith Hospital
Dean Metcalfe, M.D.
National Institute of Allery and
Infectious Diseases
Anthony J. Murgo,
M.D.
Cancer Therapy Evaluation Program, DCTD
National Cancer Institute
Scott Murphy, M.D.
University of Pennsyslvania Hospital
American Red Cross
Heike L. Pahl, Ph.D.
Center for Clinical Research
University Hospital Freiburg
Richard Pazdur, M.D.
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Josef T. Prchal, M.D.
Professor of Medicine
Baylor College of Medicine
Candido E. Rivera,
M.D., FACP
Department of Laboratory Medicine
Warren Grant Magnuson Clinical Center, NIH
Nancy S. Scher, M.D.
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Richard T. Silver,
M.D.
Division of Hematogy
New York Presbyterian Hospital
Malcolm A. Smith,
M.D., Ph.D.
Cancer Therapy Evaluation Program, DCTD
National Cancer Institute
Jerry L. Spivak, M.D.
Professor of Medicine and Oncology
Johns Hopkins University School of Medicine
David Stroncek, M.D.
Department of Transfusion Medicine
Warren Grant Magnuson Clinical Center, NIH
Martin S. Tallman,
M.D.
Division of Hematology/Oncology
Northwestern University Medical School
Ayalew Tefferi, M.D.
Professor of Medicine and Hematology
Mayo Clinic
Alain Thibault, M.D.
Global Medical Leader, Oncology
Johnson & Johnson Pharmaceutical Research and Development, L.L.C.
Juergen Thiele, M.D.
Institute of Pathology
University of Cologne
Magdalena Thurin,
Ph.D.
Cancer Diagnosis Program, DCTD
National Cancer Institute
Robert Tollen, B.S.
Kayla Advertising
Peter Ujhazy, M.D.,
Ph.D.
Organ Systems Branch
National Cancer Institute
Peter Valent, M.D.
Division of Hematology and Hemostaseology
University of Vienna
Jaye L. Viner, M.D.
Division of Cancer Prevention
National Cancer Institute
Elizabeth Wagner,
M.P.H.
Division of Blood Diseases and Resources
National Heart, Lung, and Blood Institute
Sandra R. Wolman,
M.D.
Federation of American Societies for Experimantal Biology
Institute for Social Behavior and Economic Research
John J. Wright, M.D.,
Ph.D.
Cancer Therapy Evaluation Program, DCTD
National Cancer Institute
Roy S. Wu, Ph.D.
Cancer Therapy Evaluation Program, DCTD
National Cancer Institute
Paul Zimmerman, M.D.
Center for Drug Evaluation and Research
U.S. Food and Drug Administration
Jerome B. Zeldis,
M.D., Ph.D.
Chief Medical Officer
Celgene Corporation
James A. Zweibel,
M.D., F.A.C.P.
Cancer Therapy Evaluation Program, DCTD
National Cancer Institute
top
of page
|
